JLJennifer M. Levine

Jennifer M. Levine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer M. Levine has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of v‐SYMPHONY's Virtual Boot Camp on Trainee Transition From Residency to Fellowship

    by Anshul Vagrecha, Adit L. Tal, Kayleen A. Bailey, Andrea D. Orsey, Danielle Cohen, Jessica E. Briggs, Jeremy Rosenblum, Farzana Pashankar, Katharine Offer, Alexander J. Chou, et al.

    Background: Starting a pediatric subspecialty fellowship presents numerous challenges to trainees. Virtual Symposium of Pediatric Hematology/Oncology of New York (v‐SYMPHONY), an educational collaborative organized by 18 pediatric hematology–oncology (PHO) programs, initiated an annual bootcamp in 2022 aimed at easing the transition from pediatric residency to PHO fellowship. Methods: The bootcamp consisted of virtual clinical lectures and fellow‐led panels, which were created with input from diverse program leadership, educators, and past fellows using Kern's six‐step module of curriculum development. It was offered to incoming fellows, first in the NY/NJ/CT region, and subsequently expanded nationally. Results: Over 4 years (2022–2025), 147 pediatric residents completed this virtual bootcamp. The number of residents attending the live sessions increased from 19 in 2022 to 62 in 2025. Forty‐four participants completed pre‐ and post‐bootcamp surveys over this period, which showed significant improvement in both self‐reported medical knowledge and preparedness and reported a decrease in transition to fellowship anxiety scores. Conclusion: These results highlight the need and benefits of a standardized orientation program that can be delivered virtually to ease the transition of PHO trainees from residency to fellowship. Such a standardized curriculum is feasible, adaptable, and potentially scalable to a national level.

  • Longitudinal Ovarian Reserve in Female Adolescents/Young Adults With Lymphoma: A Report From Children's Oncology Group Study ALTE11C1

    by Lindsay F. Schwartz, Clarisa R. Gracia, Venkatraman E. Seshan, Jill P. Ginsberg, Richard Aplenc, Genevieve Sylvain, Debra L. Friedman, Saro H. Armenian, Lillian R. Meacham, Eric J. Chow, et al.

    Background: Children's Oncology Group (COG) study ALTE11C1 prospectively evaluated ovarian reserve in female adolescents/young adults (AYAs) with lymphoma from diagnosis to 1 year post‐end of treatment (EOT). Healthy peers provided normative comparisons. Procedure: From 2013 to 2018, female participants ≥6 months post‐menarche with newly diagnosed lymphoma were enrolled at COG institutions, along with healthy peers. All completed study entry questionnaires and menstrual cycle‐independent blood draws for anti‐Müllerian hormone (AMH), follicle‐stimulating hormone (FSH), and estradiol; lymphoma participants had four additional draws during and after treatment. Associations between biomarkers, disease and treatment characteristics were evaluated. Logistic regression and recursive partitioning analyses identified predictors of diminished ovarian reserve (DOR: AMH p < 0.01) and 1 year post‐EOT (1.7 vs. 4.1 ng/mL; p < 0.01). AMH declined during treatment, with partial recovery post‐EOT to below study entry levels ( p < 0.01). Those with advanced stage Hodgkin lymphoma and/or B symptoms had the lowest AMH. By 1 year post‐EOT, 34% had DOR; study entry AMH less than 1 ng/mL ( p = 0.003) and higher alkylator exposure ( p = 0.01) were independent predictors. Most participants with study entry AMH less than 1 ng/mL (76%) or CED ≥6.6 g/m 2 (75%) demonstrated DOR at 1 year post‐EOT. No participant had acute ovarian failure at 1 year post‐EOT. Conclusions: Lymphoma and its treatments affect ovarian reserve in female AYA patients. Low AMH at diagnosis and high alkylator exposure predict post‐therapy DOR and can guide fertility preservation counseling.

  • Fertility Preservation Services for Adolescents and Young Adults: 2022 National Cancer Institute Community Oncology Research Program Landscape Assessment

    by Erin M. Mobley, Julie Anna Wolfson, Jennifer Levine, Lingyun Ji, Subhash Ramakrishnan, Chandylen L. Nightingale, Emily V. Dressler, Carol Kittel, David R. Freyer, Aaron J. Sugalski, et al.

    PURPOSE: Given the impact of cancer treatment on fertility among adolescents and young adults (AYAs: 15-39 years), it is important to ensure AYAs access to fertility preservation (FP). However, the availability of FP services for AYAs treated in community settings is unknown. We examined FP access at National Cancer Institute Community Oncology Research Program (NCORP) practice groups. METHODS: The 2022 NCORP Landscape Assessment survey captured available resources and cancer care services including FP services at practice groups. We described FP services as accessible (on-site or off-site) versus not accessible by AYA-treating status (as previously defined). Univariable and multivariable analyses were used to evaluate associations between FP services and practice characteristics (NCORP classification [minority/underserved or community] and proportion of Medicaid or uninsured above/below the national average). RESULTS: Among 271 practice groups responding to the survey, 100 were categorized as AYA-treating, of which 32% had neither male nor female FP services available. Sperm banking was available at 59 AYA-treating practices, among which 43 (73%) referred for sperm banking off-site. Although approximately half of AYA-treating practices reported accessible female FP services (embryo = 54%, oocyte = 55%, ovarian tissue = 40%), most of them referred patients off-site (embryo = 72%, oocyte = 80%, ovarian tissue = 83%). The odds of access to male FP were lower at minority/underserved practices (odds ratio, 0.34 [95% CI, 0.13 to 0.88]; P = .026; ref = community); however, this same relationship was not seen for females. CONCLUSION: Despite guidelines surrounding FP discussions before cancer therapy, and strong consensus regarding the importance of FP access, many AYA-treating practices in community settings lack access to FP services. Understanding how to leverage available services and broadly expand access is urgently needed to facilitate guideline-concordant, high-quality cancer care for AYAs.


  • COVID‐19 Reinfection in Children With Cancer: Clinical Course and Risk Factors

    by Pietro Miozzo, Joseph‐Michael Fields, Chen Dai, Elizabeth S. Davis, Isaac Martinez, Julienne Brackett, David S. Dickens, Alissa R. Kahn, Carla Schwalm, Archana Sharma, et al.

    While children with cancer are at risk of severe COVID‐19, little is known about reinfection. Among infections ( n = 2075) in children (≤ 21 years old, median age = 10 years old) receiving cancer‐directed therapy and reported to the Pediatric Oncology COVID‐19 case report, reinfection represented 6%. Children with subsequent infections did not have lower odds of hospitalization, intensive care unit admission, or changes to cancer‐directed therapy. Odds of reinfection were higher among children with hematologic malignancies but did not vary with sociodemographics, disease status, comorbidities, or vaccination status. The disease course for reinfected children was not less severe than the first infection, emphasizing the importance of preventing reinfection.

  • Pediatric Hematology Oncology Building Education and Training Success (PHO BEATS): A Conference to Raise Awareness and Interest for Residents and Medical Students

    by Scott Moerdler, Joanna Pierro, Adit Tal, Viviana Vidal‐Anaya, Danielle Cohen, Jessica Briggs, Kavitha Ramaswamy, Gabriel Robbins, Jeremy Rosenblum, Alexander Chou, et al.

  • COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk

    by Alissa R Kahn, Elizabeth S Davis, Chen Dai, Caroline V Caudill, Isaac Martinez, Julienne Brackett, Archana Sharma, Carla Schwalm, Ann Kebede, David S Dickens, et al.

    PURPOSE: Unlike most childhood cancers, therapy for ALL includes a prolonged maintenance phase during which children typically resume regular activities. Physicians need data regarding the persistent impact of COVID-19 in this population to help guide families after the pandemic. METHODS: The Pediatric Oncology COVID-19 Case Report (POCC) collects deidentified data (sociodemographics, clinical data [cancer, COVID-19 course]) on children, adolescents, and young adults with cancer and COVID-19 from 104 US pediatric oncology institutions. The analysis presented here compares children (≤21 years) with ALL in maintenance (ALL-MTN) with all other children with cancer and COVID-19. Multivariable analyses adjust for age, race/ethnicity, insurance, absolute neutrophil count at the time of infection, vaccination, and comorbidities. RESULTS: Compared with other children reported to POCC (n = 1,190), those in ALL-MTN (n = 481) were less often hospitalized (23% v 29%, P = .01) or admitted to the intensive care unit (ICU: 3% v 5%, P = .01); these findings persisted in multivariable analysis (hospitalization: odds ratio [OR], 0.7 [95% CI, 0.6 to 0.9]; ICU: OR, 0.5 [95% CI, 0.2 to 0.8]). However, cancer-directed therapy was changed more often for children in ALL-MTN (50% v 33%, P ≤ .01; OR, 2.0 [95% CI, 1.6 to 2.5[). Vaccination was an independent prognostic factor in our multivariable model, decreasing odds of hospitalization (OR, 0.7 [95% CI, 0.5 to 0.9]). CONCLUSION: Children in ALL-MTN required fewer hospitalizations and ICU admissions but more therapy modifications than other children with cancer. Vaccination against COVID-19 reduced the odds of hospitalization.


  • Open Access

    COVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies

    by Blake Foxworthy, Chen Dai, Elizabeth C. Davis, Ana C. Xavier, Julienne Brackett, David Dickens, Alissa Kahn, Isaac Martinez, Archana Sharma, Carla Schwalm, et al.

    Introduction: Children, adolescents, and young adults (CAYAs) with Down syndrome (DS) and hematologic malignancies are particularly vulnerable to infections and related complications. There are limited data regarding COVID‐19 infections in this group. We aimed to understand the clinical course of COVID‐19 in this population. Methods: This observational study leverages the de‐identified clinical and sociodemographic data captured by the Pediatric Oncology COVID‐19 Case Report Registry (POCC) regarding CAYAs with cancer and COVID‐19. We evaluated CAYAs (≤21 years at COVID‐19 infection) with hematologic malignancies and COVID‐19 reported from April 1, 2020 to May 2, 2023, comparing those with and without DS. Using multivariable logistic regression, we examined rates of hospitalization, intensive care unit (ICU) admission, respiratory support, and changes in cancer‐directed therapy. Results: Among 1408 CAYAs with hematologic malignancies, 55 had DS (CAYA‐DS). CAYA‐DS had higher rates of hospitalization, ICU admission, and respiratory support ( p < .001) than CAYAs without DS. Similarly, multivariable analyses found higher odds of hospitalization (odds ratio [OR] = 2.8, 95% confidence interval [CI]: 1.5–5.1), ICU admission (OR = 4.2, 95% CI: 1.9–9.1), and need for respiratory support (OR = 4.2, 95% CI: 2.0–8.8) among CAYA‐DS. Modifications to cancer‐directed therapy were more common among CAYA‐DS when related to neutropenia ( p = .001), but not when unrelated to neutropenia ( p = .88); CAYA‐DS did not have higher odds of changes to cancer‐directed therapy (OR = 1.20, 95% CI: 0.7–2.1). Conclusions: We identify CAYA‐DS with hematologic malignancies as a vulnerable subpopulation at greater risk for severe COVID‐19 infection. This can inform conversations with patients and families regarding therapeutic and preventive measures, as well as the risks and benefits of modifying chemotherapy in the setting of COVID‐19.

  • Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL

    by Julie A. Wolfson, Allison C. Grimes, Michelle Nuno, Charlotte L. Kerber, Subhash Ramakrishnan, Melissa Beauchemin, David Dickens, Jennifer M. Levine, Michael E. Roth, Michele Scialla, et al.

    PURPOSE: Individuals diagnosed with cancer between 15 and 39 years (adolescent and young adult [AYA]) face unique vulnerability. Detail is lacking about care delivery for these patients, especially those with ALL. We address these knowledge gaps by describing AYA ALL care delivery details at National Cancer Institute Community Oncology Research Program (NCORP) (sub)affiliates by model of care. METHODS: Participating institutions treated at least one AYA with ALL from 2012 to 2016. Study-specific criteria were used to determine the number of unique clinical facilities (CFs) per NCORP and their model of care (adult/internal medicine [IM], pediatric, mixed [both]). Surveys completed by NCORPs for each CF by model of care captured size, resources, services, and communication. RESULTS: Among 84 participating CFs (adult/IM, n=47; pediatric, n=15; mixed, n=24), 34% treated 5-10 AYAs with ALL annually; adult/IM CFs more often treated <5 (adult/IM, 60%; pediatric, 40%; mixed, 29%). Referral decisions were commonly driven by an age/diagnosis combination (58%), with frequent ALL-specific age minimums (87%) or maximums (80%). Medical, navigational, and social work services were similar across models while psychology was available at more pediatric CFs (pediatric, 80%; adult/IM, 40%; mixed, 46%-54%). More pediatric or mixed CFs reported oncologists interacting with pediatric/adult counterparts via tumor boards (pediatric, 93%; adult/IM, 26%; mixed, 96%) or initiating contact (pediatric, 100%; adult/IM, 77%; mixed 96%); more pediatric CFs reported an affiliated counterpart (pediatric, 53%; adult, 19%). Most CFs reported no AYA-specific resources (79%) or meetings (83%-98%). CONCLUSION: System-level aspects of AYA ALL care delivery have not been examined previously. At NCORPs, these characteristics differ by models of care. Additional work is ongoing to investigate the impact of these facility-level factors on guideline-concordant care in this population. Together, these findings can inform a system-level intervention for diverse practice settings.


  • Open Access

    COVID-19 Infection in Children with Acute Lymphoblastic Leukemia Receiving Maintenance Therapy: Don’t Discount the Risk

    by Alissa Kahn, Elizabeth Davis S, Caroline Caudill, Isaac Martinez, Julienne Brackett, Archana Sharma, Carla Schwalm, Ann Kebede, David Dickens, Joshua Richman, et al.

    Background: Unlike other pediatric cancers, acute lymphoblastic leukemia (ALL) treatment includes a prolonged maintenance phase during which children typically resume regular activities. As COVID-19 transmission persists despite the end of the public health emergency declaration, physicians need data regarding the impact of COVID-19 in this population to guide families in managing risk. Procedure: The Pediatric Oncology COVID-19 Case Report (POCC) collected de-identified clinical and sociodemographic data on children with cancer and COVID-19. This subset analysis compares 481 children (≤21yo at COVID-19 infection) with ALL in maintenance (ALL-MTN) to other children with cancer and COVID-19 (n=1,190). Results: Children in ALL-MTN had fewer hospitalizations, (23% vs 29%, p=0.01), intensive care unit admissions (ICU: 3% vs 5%, p=0.01), and were less likely to die (0% vs 2%, p=<0.01). However, they more often had cancer therapy changed (50% vs 33%, p=<0.01). Lower odds of hospitalization and ICU admission persisted in multivariable analyses adjusting for age, race/ethnicity, insurance, ANC, and comorbidities. There were independent associations among children in ALL-MTN with sociodemographic factors (Hispanic ethnicity, public insurance) and clinical characteristics (comorbid conditions, neutropenia) and both hospitalization and ICU admission. Vaccination decreased odds of hospitalization. Conclusions: Children in ALL-MTN continue to have significant COVID-19 risks, with less hospitalization and ICU admission but more therapy changes than other children with cancer. These risks should be addressed when discussing participation in activities (school, camp, sports, etc.), prevention (COVID-19 vaccination) and mitigation (masking) strategies. The high level of therapy modifications could have long-term consequences and should continue to be followed.

  • Open Access

    Understanding Causes of Inferior Outcomes in Adolescents and Young Adults With Cancer

    by Julie A. Wolfson, Kelly M. Kenzik, Blake Foxworthy, John M. Salsman, Katherine Donahue, Marie Nelson, Mary Beth Littrell, Grant R. Williams, Jennifer M. Levine

    Individuals diagnosed with cancer as adolescents and young adults (AYAs; ages 15–39 years) face unique vulnerabilities. Compared with individuals diagnosed when younger (≤14 years) or older (≥40 years), AYAs have not seen the same improvement in survival. Furthermore, they sit at a complex moment of social, emotional, and cognitive development, and have a unique interface with the healthcare system. With these observations, NCI prioritized addressing the unique vulnerabilities among AYAs with cancer, and NCCN developed guidelines regarding optimal AYA cancer care. Improvements in certain locales have been seen in the wake of this focus on AYAs, suggesting that continuing to consider AYA outcomes in the context of their specific needs is critical as we strive toward additional improvements. However, it is key to consider the drivers of these outcomes to continue this trajectory. This review presents a holistic conceptual model that includes factors that influence outcomes among AYAs with cancer, including domains in these levels that influence both clinical outcomes (such as relapse and survival) and health-related quality of life (HRQoL). These include domains at the patient level, such as social constructs (race/ethnicity, socioeconomic status), behavior (adherence, risk-taking), biologic characteristics (cancer biology, host genetics), medical treatment (treatment regimen, risk-based survivorship care), and treatment-related toxicities. The model also includes domains at the system level, which include treatment location (NCI designation, facility model, AYA program presence), clinical trial enrollment, transdisciplinary communication, fertility preservation, and psychosocial support. Recognizing these multiple factors at the level of the individual and the healthcare system influence AYA outcomes (from HRQoL to survival), it is key not only to consider patient-level interventions and development of novel cancer agents but also to develop systems-level interventions that can be executed in parallel. In this way, the impact can be expanded to a vast number of AYAs.